Related references
Note: Only part of the references are listed.Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Clinical Use of Interferon-gamma
Catriona H. T. Miller et al.
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS (2009)
Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules
Sara J. Adair et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma
Atsushi Natsume et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells
Javier Carrasco et al.
JOURNAL OF IMMUNOLOGY (2008)
Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities
Matthias Wolfl et al.
BLOOD (2007)
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura
David S. Schrump et al.
CLINICAL CANCER RESEARCH (2006)
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
S. Fulda et al.
ONCOGENE (2006)
In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire
WY Ho et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2006)
Tumor antigen expression in melanoma varies according to antigen and stage
C Barrow et al.
CLINICAL CANCER RESEARCH (2006)
Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid
H Yang et al.
LEUKEMIA RESEARCH (2005)
Future directions for the use of hypomethylating agents
G Garcia-Manero et al.
SEMINARS IN HEMATOLOGY (2005)
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate
JPJ Issa et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Evaluation of a 7-day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation
WE Samlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma
M Wölfl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
MAGE-Al-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
KA Chianese-Bullock et al.
JOURNAL OF IMMUNOLOGY (2005)
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1
HA Vaughan et al.
CLINICAL CANCER RESEARCH (2004)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Expression of cancer/testis (CT) antigens in lung cancer
K Tajima et al.
LUNG CANCER (2003)
Neuroblastoma: Biological insights into a clinical enigma
GM Brodeur
NATURE REVIEWS CANCER (2003)
Adoptive transfer of costimulated CD4(+) T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection
BL Levine et al.
NATURE MEDICINE (2002)
Expression of HLA class I antigens and restoration of antigen-specific ctl response in melanoma cells following 5-aza-2′-deoxycytidine treatment
A Serrano et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Induction of primary NY-ESO-1 immunity:: CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+cancers
E Jäger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen
Q Sun et al.
JOURNAL OF IMMUNOLOGY (2000)
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
T Teitz et al.
NATURE MEDICINE (2000)
Share Paper
